A Cost-Effective and Non-Invasive pfeRNA-Based Test Differentiates Benign and Suspicious Pulmonary Nodules from Malignant Ones
Authors:
Open Access
- 16 December 2021
- journal article
- research article
- Published by MDPI AG in Non-Coding RNA
- Vol. 7 (4) , 80
Abstract
The ability to differentiate between benign, suspicious, and malignant pulmonary nodules is imperative for definitive intervention in patients with early stage lung cancers. Here, we report that plasma protein functional effector sncRNAs (pfeRNAs) serve as non-invasive biomarkers for determining both the existence and the nature of pulmonary nodules in a three-stage study that included the healthy group, patients with benign pulmonary nodules, patients with suspicious nodules, and patients with malignant nodules. Following the standards required for a clinical laboratory improvement amendments (CLIA)-compliant laboratory-developed test (LDT), we identified a pfeRNA classifier containing 8 pfeRNAs in 108 biospecimens from 60 patients by sncRNA deep sequencing, deduced prediction rules using a separate training cohort of 198 plasma specimens, and then applied the prediction rules to another 230 plasma specimens in an independent validation cohort. The pfeRNA classifier could (1) differentiate patients with or without pulmonary nodules with an average sensitivity and specificity of 96.2% and 97.35% and (2) differentiate malignant versus benign pulmonary nodules with an average sensitivity and specificity of 77.1% and 74.25%. Our biomarkers are cost-effective, non-invasive, sensitive, and specific, and the qPCR-based method provides the possibility for automatic testing of robotic applications.Keywords
Funding Information
- National Institutes of Health (UH3CA239137)
- State Key Laboratory of Respiratory Disease (SKLRD-OP-202213)
- AstraZeneca (Sweden) (130604)
This publication has 49 references indexed in Scilit:
- Evaluation of Individuals With Pulmonary Nodules: When Is It Lung Cancer?Chest, 2013
- Lung cancer in never smokers – A reviewEuropean Journal of Cancer, 2012
- Decision Making in Patients with Pulmonary NodulesAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- Developing a Standard Protocol for the Introduction of New Testing Into a Clinical Laboratory: Appendix 1Laboratory Medicine, 2009
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non–Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group TrialsJournal of Clinical Oncology, 2008
- T1 Lung Cancers: Sensitivity of Diagnosis with Fluorodeoxyglucose PETRadiology, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001